Tender opportunity: Clinical Trial Readiness through the Establishment of a Pilot Filovirus Investigational Vaccine Reserve

DG HERA, in collaboration with its executive agency, HaDEA, would like to inform you that it has launched a new tender procedure:

Clinical Trial Readiness through the Establishment of a Pilot Filovirus Investigational Vaccine Reserve (HADEA/2026/OP/0019) 💉 🩸

This call for tenders aims to ensure clinical trial preparedness for Filovirus outbreaks through the establishment of an EU-based reserve of investigational vaccines as a critical preparedness measure, given the sporadic yet high-consequence nature of these pathogens. Specifically, the call has the objective of establishing, piloting and maintaining a reserve of candidate vaccines targeting human-pathogenic filoviruses for which no authorized vaccines are currently available (Marburg virus (MARV), Sudan virus (SUDV), Bundibugyo virus (BDBV)), which, in case of an outbreak, could be used to advance their development. These provisions would allow for the rapid deployment of candidate vaccines at a later stage. Tenderers will further have to ensure the rapid deployment of the investigational doses, subject to specific conditions being met (such as the occurrence of an outbreak and the expressed consent of the Contracting Authority).

• Indicative type of procedure: Open call for tenders
• Indicative type of contract: Direct contract
• Total budget: EUR 16 million, with an expected 1 tenderer to be awarded.
• Project duration: 48 months.
• Target applicants: Higher education institutions, research organisations, vaccine developers, hospitals and healthcare institutions, NGOs, other private or public entities with expertise in vaccine development.

Interested parties are invited to consult the EU Funding and Tenders Portal (F&Ts Portal) for information on the contract notice and tender documents, in particular the draft service contract and the tender specifications, and to submit their proposals via the EU Funding and Tender Portal by 2 September 2026.

Prospective tenderers are encouraged to monitor the F&Ts Portal regularly, as the procedure webpage is the sole authoritative source for updates, clarifications, and any modifications to the tender documents. DG HERA and HaDEA websites and social media channels will also relay relevant announcements:

DG HERA website and social media

HaDEA website and social media

For any questions, you may contact the Belgium National Focal Points for the EU4Health Programme: https://hadea.ec.europa.eu/programmes/eu4health/national-focal-points_en .